9-Month Clinical, Angiographic, and Intravascular Ultrasound Results of a Prospective Evaluation of the Axxess Self-Expanding Biolimus A9-Eluting Stent in Coronary Bifurcation LesionsThe DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) Study
Stefan Verheye, MD, PhD*,*,
Pierfrancesco Agostoni, MD*,
Christophe L. Dubois, MD ,
Joseph Dens, MD, PhD ,
John Ormiston, MD ,
Stephen Worthley, MD||,
Brett Trauthen, MS¶,
Takao Hasegawa, MD#,
Bon-Kwon Koo, MD, PhD#,
Peter J. Fitzgerald, MD, PhD#,
Roxana Mehran, MD** and
Alexandra J. Lansky, MD**
* Antwerp Cardiovascular Institute Middelheim, Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium
University Hospital Gasthuisberg, Leuven, Belgium
Oost-Limburg Hospital, Genk, Belgium
Auckland City Hospital, Auckland, New Zealand
|| Royal Adelaide Hospital, Adelaide, Australia
¶ Devax, Inc., Lake Forest, California
# Stanford University Medical Center, Stanford, California
** Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York

View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Final Placement Angiogram
(A) Contrast-filled angiogram shows the Axxess stent in the proximal left anterior descending artery (LAD) (left anterior oblique artery view with 1 marker at the level of the mid-LAD and 2 markers in the diagonal branch) and an additional Cypher in the mid-LAD. (B) Stent boost image shows an enhanced contrast-negative stent visualization.
|
|

View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Flow Diagram of Subjects' Progress Through Phases of the DIVERGE Study
DIVERGE = Drug-Eluting Stent Intervention for Treating Side Branches Effectively; FU = follow-up; IVUS = intravascular ultrasound.
|
|
|